Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Crinetics Pharmaceuticals, Inc. - Common Stock (NQ:CRNX)

46.02 -1.59 (-3.35%)
Streaming Delayed Price Updated: 11:59 AM EST, Feb 12, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 189,608
Open 48.41
Bid (Size) 45.89 (100)
Ask (Size) 46.15 (200)
Prev. Close 47.61
Today's Range 45.90 - 48.41
52wk Range 24.10 - 57.99
Shares Outstanding 54,026,103
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
Crinetics Pharmaceuticals to Participate in Two Upcoming Investor Conferences in March
From Crinetics Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Corcept Therapeutics (CORT): A Deep Dive into the 43.7% Earnings Growth and the High-Stakes Pivot to Oncology
As of January 28, 2026, Corcept Therapeutics (NASDAQ: CORT) stands at a critical crossroads that perfectly encapsulates the high-stakes nature of the biotechnology sector. Once a niche player focused... 
Via Finterra
Topics Economy Intellectual Property

Performance

YTD
-1.5%
-1.5%
1 Month
-16.9%
-16.9%
3 Month
+7.5%
+7.5%
6 Month
+52.9%
+52.9%
1 Year
+31.7%
+31.7%

More News

Read More
News headline image
Crinetics Pharmaceuticals to Report Fourth Quarter and Full Year 2025 Financial Results on February 26, 2026
From Crinetics Pharmaceuticals, Inc.
Via GlobeNewswire
CRNX Stock Gains, NBIX Shares Drop On Positive Results From Genetics Disorder Trial ↗
Via Stocktwits
News headline image
Crinetics Initiates Phase 2/3 Pediatric Trial Evaluating Atumelnant in Congenital Adrenal Hyperplasia (CAH)
From Crinetics Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Crinetics Pharmaceuticals Announces January 2026 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Crinetics Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Earnings Scheduled For November 6, 2025 ↗
Via Benzinga
The market is filled with gapping stocks in Wednesday's session. ↗
Via Chartmill
News headline image
Crinetics Pharmaceuticals Announces Pricing of Public Offering of Common Stock
From Crinetics Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Crinetics Pharmaceuticals Announces Proposed Public Offering of Common Stock
From Crinetics Pharmaceuticals, Inc.
Via GlobeNewswire
Wondering what's happening in today's pre-market session? ↗
Via Chartmill
News headline image
Crinetics Announces Strong PALSONIFY Launch Execution and Positive Results for Concurrent Androstenedione Lowering and Glucocorticoid Dose Reduction in Phase 2 Trial of Atumelnant for Congenital Adrenal Hyperplasia
From Crinetics Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Crinetics Pharmaceuticals to Provide PALSONIFY Business Update and Announce Topline Results from Fourth Cohort of Phase 2 Trial of Atumelnant in Congenital Adrenal Hyperplasia
From Crinetics Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Crinetics Pharmaceuticals to Participate in The 44th Annual J.P. Morgan Healthcare Conference
From Crinetics Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Crinetics Announces First Patient Dosed in Pivotal Adult Trial of Atumelnant in Congenital Adrenal Hyperplasia (CAH)
From Crinetics Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Crinetics Pharmaceuticals Announces December 2025 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Crinetics Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Crinetics Announces First Patient Dosed in Phase 1/2 Trial Evaluating CRN09682 for the Treatment of Neuroendocrine Tumors and Other Somatostatin Receptor 2-Expressing Tumors
From Crinetics Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Biotech Fund Dumps $12.3 Million in Crinetics Stock as Shares Remain 19% Lower on the Year ↗
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Crinetics Announces First Patient Randomized in Pivotal Phase 3 CAREFNDR Trial Evaluating Paltusotine in Carcinoid Syndrome
From Crinetics Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Crinetics Pharmaceuticals Announces November 2025 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Crinetics Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Why Crinetics Pharmaceuticals Stock Was Sliding on Friday ↗
Via The Motley Fool
News headline image
Crinetics Pharmaceuticals Inc (NASDAQ:CRNX) Emerges as a Technical Breakout Candidate ↗
Via Chartmill
News headline image
Crinetics Pharmaceuticals (NASDAQ:CRNX) Reports Q3 2025 Earnings Miss ↗
Via Chartmill
Topics Earnings
News headline image
Crinetics Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides Business Update
From Crinetics Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Crinetics to Highlight Neuroendocrine Tumor Research Progress at the 2025 North American Neuroendocrine Tumor Society Annual Meeting
From Crinetics Pharmaceuticals, Inc.
Via GlobeNewswire

Frequently Asked Questions

Is Crinetics Pharmaceuticals, Inc. - Common Stock publicly traded?
Yes, Crinetics Pharmaceuticals, Inc. - Common Stock is publicly traded.
What exchange does Crinetics Pharmaceuticals, Inc. - Common Stock trade on?
Crinetics Pharmaceuticals, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Crinetics Pharmaceuticals, Inc. - Common Stock?
The ticker symbol for Crinetics Pharmaceuticals, Inc. - Common Stock is CRNX on the Nasdaq Stock Market
What is the current price of Crinetics Pharmaceuticals, Inc. - Common Stock?
The current price of Crinetics Pharmaceuticals, Inc. - Common Stock is 46.02
When was Crinetics Pharmaceuticals, Inc. - Common Stock last traded?
The last trade of Crinetics Pharmaceuticals, Inc. - Common Stock was at 02/12/26 11:59 AM ET
What is the market capitalization of Crinetics Pharmaceuticals, Inc. - Common Stock?
The market capitalization of Crinetics Pharmaceuticals, Inc. - Common Stock is 2.49B
How many shares of Crinetics Pharmaceuticals, Inc. - Common Stock are outstanding?
Crinetics Pharmaceuticals, Inc. - Common Stock has 2B shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.